Original Study| Volume 22, ISSUE 10, P2190-2195, October 2021

Renin-Angiotensin System Inhibitors Prognostic Benefit in Older Patients with Atrial Fibrillation

Published:February 16, 2021DOI:



      Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-receptor blockers (ARB) have shown antiarrhythmic effects that are useful as part of the upstream therapy for atrial fibrillation (AF), both for primary and secondary prevention. Nevertheless, the potential prognosis value of these drugs in terms of mortality and major cardiovascular events is unclear, especially in older population with AF. Scientific evidence is scarce in this population and shows contradictory results. The aim of this study was to assess the potential benefit of ACEi and ARB in terms of mortality and major cardiovascular outcomes (hospitalization for heart failure, acute myocardial infarction and stroke) in older patients with AF, based on a real-world data analysis.


      Observational: analysis of a retrospective registry.

      Settings and Participants

      The study included 9365 patients of 75 years or older diagnosed with AF, from CardioCHUVI-AF_75 registry: Identifier: NCT04364516. Date of registration: November 26, 2018.


      We performed propensity score matching techniques to obtain 2 comparable groups of 3601 patients with and without ACEi or ARB treatment. We compared survival and cardiovascular outcomes in both groups of patients using Cox proportional hazards models.


      We did not find significant differences in terms of survival between using or not using ACEi or ARB for the older population (hazard ratio for mortality: 0.959, 95% confidence interval 0.872–1.054). There were no significant differences regarding cardiovascular major events between the 2 groups.

      Conclusions and Implications

      Treatment with ACEi or ARB did not improve outcomes in terms of survival and cardiovascular events in older patients with AF. These results should prompt the conduct of randomized clinical trials specifically in the older AF patient population to robustly address this issue.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Savelieva I.
        • Kakouros N.
        • Kourliouros A.
        • Camm A.J.
        Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology Guidelines. Part I: Primary prevention.
        Europace. 2011; 13: 308-328
        • Lau D.H.
        • Nattel S.
        • Kalman J.M.
        • Sanders P.
        Modifiable risk factors and atrial fibrillation.
        Circulation. 2017; 136: 583-596
        • Serra J.L.
        • Bendersky M.
        Atrial fibrillation and renin-angiotensin system.
        Ther Adv Cardiovasc Dis. 2008; 2: 215-223
        • Bisbal F.
        • Baranchuk A.
        • Braunwald E.
        • et al.
        Atrial failure as a clinical entity: JACC review topic of the week.
        J Am Coll Cardiol. 2020; 75: 222-232
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • et al.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
        J Am Coll Cardiol. 2014; 64: e1-76
        • January C.T.
        • Wann L.S.
        • Calkins H.
        • et al.
        2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons.
        Circulation. 2019; 140: e125-e151
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • et al.
        2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37: 2893-2962
        • Hindricks G.
        • Potpara T.
        • Dagres N.
        • et al.
        2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).
        Eur Heart J. 2021; 42: 373-498
        • Wachtell K.
        • Hornestam B.
        • Lehto M.
        • et al.
        Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study.
        J Am Coll Cardiol. 2005; 45: 705-711
        • Yusuf S.
        • Healey J.S.
        • Pogue J.
        • et al.
        Irbesartan in patients with atrial fibrillation.
        N Engl J Med. 2011; 364: 928-938
        • Lip G.Y.
        • Frison L.
        • Grind M.
        Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
        J Intern Med. 2007; 261: 577-586
        • Cobas Paz R.
        • Raposeiras Roubín S.
        • Abu Assi E.
        • et al.
        Impact of anticoagulation in patients with dementia and atrial fibrillation. Results of the CardioCHUVI-FA registry.
        Rev Esp Cardiol (Engl Ed). 2020; 73: 877-884
        • Hicks K.A.
        • Mahaffey K.W.
        • Mehran R.
        • et al.
        2017 Cardiovascular and stroke endpoint definitions for clinical trials.
        Circulation. 2018; 137: 961-972
        • Gómez-Outes A.
        • Lagunar-Ruíz J.
        • Terleira-Fernández A.I.
        • et al.
        Causes of death in anticoagulated patients with atrial fibrillation.
        J Am Coll Cardiol. 2016; 68: 2508-2521
        • Marott S.C.
        • Nielsen S.F.
        • Benn M.
        • Nordestgaard B.G.
        Antihypertensive treatment and risk of atrial fibrillation: A nationwide study.
        Eur Heart J. 2014; 35: 1205-1214
        • Raposeiras-Roubín S.
        • Abu-Assi E.
        • Cespón-Fernández M.
        • et al.
        Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction.
        Rev Esp Cardiol (Engl Ed). 2020; 73: 114-122
        • Donoghue O.A.
        • Jansen S.
        • Dooley C.
        • et al.
        Atrial fibrillation is associated with impaired mobility in community-dwelling older adults.
        J Am Med Dir Assoc. 2014; 15: 929-933
        • Yamashita T.
        • Inoue H.
        • Okumura K.
        • et al.
        Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
        Europace. 2011; 13: 473-479
        • Disertori M.
        • Latini R.
        • Barlera S.
        • et al.
        Valsartan for prevention of recurrent atrial fibrillation.
        N Engl J Med. 2009; 360: 1606-1617
        • Kopecky S.L.
        • Gersh B.J.
        • McGoon M.D.
        • et al.
        The natural history of lone atrial fibrillation. A population-based study over three decades.
        N Engl J Med. 1987; 317: 669-674
        • Pfeffer M.A.
        • McMurray J.J.
        • Velazquez E.J.
        • et al.
        Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
        N Engl J Med. 2003; 349: 1893-1906
        • Li E.C.
        • Heran B.S.
        • Wright J.M.
        Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
        Cochrane Database Syst Rev. 2014; : CD009096